Northern Trust’s Biostage, Inc. Common Stock BSTG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-46,453
| Closed | -$14K | – | 4327 |
|
|
2017
Q3 | $14K | Buy |
46,453
+20,701
| +80% | +$8.29K | ﹤0.01% | 4181 |
|
|
2017
Q2 | $11K | Hold |
25,752
| – | – | ﹤0.01% | 4219 |
|
|
2017
Q1 | $10K | Buy |
25,752
+6,611
| +35% | +$3.62K | ﹤0.01% | 4196 |
|
|
2016
Q4 | $17K | Buy |
19,141
+26
| +0.1% | +$23 | ﹤0.01% | 4115 |
|
|
2016
Q3 | $20K | Sell |
19,115
-481
| -2% | -$518 | ﹤0.01% | 4107 |
|
|
2016
Q2 | $22K | Buy |
19,596
+4,226
| +27% | +$6.82K | ﹤0.01% | 4110 |
|
|
2016
Q1 | $28K | Sell |
15,370
-4,226
| -22% | -$7.01K | ﹤0.01% | 4096 |
|
|
2015
Q4 | $42K | Hold |
19,596
| – | – | ﹤0.01% | 4080 |
|
|
2015
Q3 | $17K | Buy |
19,596
+2,457
| +14% | +$2.78K | ﹤0.01% | 4196 |
|
|
2015
Q2 | $25K | Sell |
17,139
-2,322
| -12% | -$5.69K | ﹤0.01% | 4129 |
|
|
2015
Q1 | $64K | Sell |
19,461
-1,285
| -6% | -$4.38K | ﹤0.01% | 4119 |
|
|
2014
Q4 | $66K | Buy |
20,746
+49
| +0.2% | +$243 | ﹤0.01% | 4058 |
|
|
2014
Q3 | $168K | Sell |
20,697
-52,367
| -72% | -$429K | ﹤0.01% | 3888 |
|
|
2014
Q2 | $764K | Sell |
73,064
-10,521
| -13% | -$89.6K | ﹤0.01% | 3490 |
|
|
2014
Q1 | $758K | Sell |
83,585
-5,970
| -7% | -$35.4K | ﹤0.01% | 3462 |
|
|
2013
Q4 | $425K | Buy |
+89,555
| New | +$419K | ﹤0.01% | 3540 |
|
Northern Trust's BSTG Position: Q4 2017 in Review
Northern Trust sold out of Biostage, Inc. Common Stock (BSTG) in Q4 2017, closing a stake of 46,453 shares — an estimated $14K sold.
Northern Trust first reported a position in BSTG in Q4 2013 and held it in 16 quarters. The position peaked at $764K in Q2 2014. 0 funds tracked by Wall St. Rank hold BSTG as of Q4 2017.
- Northern Trust reported no remaining Biostage, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
- Northern Trust sold 46,453 Biostage, Inc. Common Stock shares in Q4 2017, an estimated $14K.
- Northern Trust first reported a position in Biostage, Inc. Common Stock in Q4 2013 and held it in 16 quarters.
- Northern Trust's Biostage, Inc. Common Stock position peaked at $764K in Q2 2014.
- 0 funds tracked by Wall St. Rank held Biostage, Inc. Common Stock as of Q4 2017.
Based on Northern Trust's 13F filing for Q4 2017, filed 14 Feb 2018.